Nanalysis Scientific Reports Strong Fourth Quarter Performance
Achieves Record Quarterly Adjusted EBITDA of at least $1 Million and Positive Free Cash-Flow
Nanalysis Scientific Corp., (TSXV: NSCI), (OTCQX: NSCIF), a leader in portable NMR instruments and imaging technology, has reported an impressive preview of its fourth quarter financials. The company anticipates achieving an adjusted EBITDA of over $1 million while generating revenue of at least $11 million for the three-month period, setting a new standard for growth.
CEO Sean Krakiwsky states: "As we reflect on the closing of the fiscal year, we are proud of our achievements. The projected positive adjusted EBITDA and significant revenue growth compared to the same period last year underscore our strategic focus on enhancing profitability and cash flow. This quarter, we see a growth of approximately $1.2 million in revenue and $1.8 million in adjusted EBITDA compared to Q4 2023."
This successful quarter marks a continuation of the company’s trend of increasing adjusted EBITDA and positive cash flows, particularly in its expanding airport security services sector. This past six quarters have seen a shift as meaningful revenues have emerged in this area, allowing for significant financial improvements.
Financial and Operational Highlights
New Adjusted EBITDA Record: For Q4 2024, the projected revenue of at least $11 million is a direct result of both the burgeoning security services segment and robust performance in Benchtop NMR sales.
- Co-Published Study with the United States Pharmacopeia (USP): A recent study concluded that Benchtop NMR is effective for quality control of active pharmaceutical ingredients (API), thus facilitating its usage in pharmaceutical quality management.
- 100 MHz Benchtop NMR Sales: In Q4, the company reported sales of 15 units of the 100 MHz Benchtop NMR, achieving its highest sales figures since clearing its backlog in 2022, demonstrating strong market demand.
- Positive Trends in Security Services: The company has reported around $26 million in 2024 revenue from its security services division, with efforts to enhance gross margins yielding positive results.
- Innovation and IP Expansion: Nanalysis continues to bolster its intellectual property portfolio with two recent patent grants related to its NMR technology, solidifying its competitive edge in materials science.
Future Outlook and Strategy
Nanalysis has plans to unveil new developments concerning its Benchtop NMR technology at upcoming exhibitions, enhancing its presence in the scientific community. As part of their strategic roadmap, they are adopting a modular approach to their Enterprise Resource Planning (ERP) implementation, aimed at optimizing operational control and efficiency moving forward.
Despite reporting positive EBITDA and cash flows in 2024, the company acknowledges it faced some challenges with net income, which will be addressed in their forthcoming financials. Looking ahead, the firm remains focused on understanding potential trade impacts and fostering growth in operational margins.
About Nanalysis Scientific Corp.
Nanalysis specializes in two primary business factions: Scientific Equipment and Security Services. Renowned for its pioneering developments in portable NMR technology, the company has established itself as a key player in various industries including pharmaceuticals, agriculture, and law enforcement, striving to tap into new markets both independently and through partnerships.
In 2022, Nanalysis secured a significant contract worth $160 million over five years to maintain passenger screening equipment across Canadian airports, further expanding its security services arm. Through innovation and reliable partnerships, Nanalysis aims to continue its trajectory of growth while enhancing the quality of its offerings.
Frequently Asked Questions
1. What were the main achievements of Nanalysis for Q4 2024?
Nanalysis is set to report an adjusted EBITDA of more than $1 million and revenue of at least $11 million, indicating significant growth from the previous year.
2. How has Nanalysis's market strategy evolved?
The company focuses on expanding its airport security services and enhancing the performance of its Benchtop NMR product line, while also integrating ERP systems for improved operational efficiency.
3. What key markets does Nanalysis serve?
Nanalysis serves a diverse array of sectors including pharmaceuticals, agriculture, and law enforcement, and aims for further market expansion.
4. How is Nanalysis driving innovation?
The company is consistently investing in its research and development efforts, exemplified by recent patent grants that enhance its product offerings and market competitiveness.
5. What is the company’s financial outlook moving forward?
Nanalysis is concentrating on achieving substantial positive EBITDA growth and maintaining positive cash flow while navigating potential trade implications as it enters 2025.
